Inclusion body myositis (IBM) and polymyositis can normally be distinguished on the basis of clinical features. However, patients with an atypical disease presentation, particularly those with early-stage disease, can be challenging to diagnose. Can imaging with amyloid-PET help distinguish these two diseases?
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Greenberg, S. A. Inclusion body myositis: clinical features and pathogenesis. Nat. Rev. Rheumatol. https://doi.org/10.1038/s41584-019-0186-x (2019).
Lilleker, J. B. et al. [18F]Florbetapir positron emission tomography: identification of muscle amyloid in inclusion body myositis and differentiation from polymyositis. Ann. Rheum. Dis. 78, 657–662 (2019).
Chahin, N. & Engel, A. G. Correlation of muscle biopsy, clinical course, and outcome in PM and sporadic IBM. Neurology 70, 418–424 (2008).
Pruitt, J. N. 2nd, Showalter, C. J. & Engel, A. G. Sporadic inclusion body myositis: counts of different types of abnormal fibers. Ann. Neurol. 39, 139–143 (1996).
Wong, D. F. et al. In vivo imaging of amyloid deposition in Alzheimer disease using the radioligand 18F-AV-45 (florbetapir [corrected] F 18). J. Nucl. Med. 51, 913–920 (2010).
Sherriff, F. E. et al. Ubiquitinated inclusions in inclusion-body myositis patients are immunoreactive for cathepsin D but not beta-amyloid. Neurosci. Lett. 194, 37–40 (1995).
Park, M. A. et al. 18F-Florbetapir binds specifically to myocardial light chain and transthyretin amyloid deposits: autoradiography study. Circ. Cardiovasc. Imaging 8, e002954 (2015).
Pinal-Fernandez, I. et al. Thigh muscle MRI in immune-mediated necrotising myopathy: extensive oedema, early muscle damage and role of anti-SRP autoantibodies as a marker of severity. Ann. Rheum. Dis. 76, 681–687 (2017).
Tasca, G. et al. Magnetic resonance imaging pattern recognition in sporadic inclusion-body myositis. Muscle Nerve 52, 956–962 (2015).
Lloyd, T. E. et al. Cytosolic 5′-nucleotidase 1A as a target of circulating autoantibodies in autoimmune diseases. Arthritis Care Res. 68, 66–71 (2016).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Pinal-Fernandez, I., Mammen, A.L. Amyloid-PET: a new tool for diagnosing IBM?. Nat Rev Rheumatol 15, 321–322 (2019). https://doi.org/10.1038/s41584-019-0223-9
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0223-9
This article is cited by
-
PET Scan: Nuclear Medicine Imaging in Myositis
Current Rheumatology Reports (2019)